Testing the running of the cosmological constant with Type Ia Supernovae at high z

Within the Quantum Field Theory context the idea of a "cosmological constant" (CC) evolving with time looks quite natural as it just reflects the change of the vacuum energy with the typical energy of the universe. In the particular frame of Ref.[30], a "running CC" at low energies may arise from generic quantum effects near the Planck scale, M_P, provided there is a smooth decoupling of all massive particles below M_P. In this work we further develop the cosmological consequences of a "running CC" by addressing the accelerated evolution of the universe within that model. The rate of change of the CC stays slow, without fine-tuning, and is comparable to H^2 M_P^2. It can be described by a single parameter, \nu, that can be determined from already planned experiments using SNe Ia at high z. The range of allowed values for \nu follow mainly from nucleosynthesis restrictions. Present samples of SNe Ia can not yet distinguish between a "constant" CC or a "running" one. The numerical simulations presented in this work show that SNAP can probe the predicted variation of the CC either ruling out this idea or confirming the evolution hereafter expected.Comment: LaTeX, 51 pages, 13 figures, 1 table, references added, typos corrected, version accepted in JCA

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Background: Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes. Methods: We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18–85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR)25–75 mL/min per 1·73 m 2 of body surface area, and a urine albumin-to-creatinine ratio (UACR)of 300–5000 mg/g who had received maximum labelled or tolerated renin–angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders)were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≥30 days)or end-stage kidney disease (eGFR <15 mL/min per 1·73 m 2 sustained for ≥90 days, chronic dialysis for ≥90 days, kidney transplantation, or death from kidney failure)in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532. Findings: Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325)or placebo group (n=1323). Median follow-up was 2·2 years (IQR 1·4–2·9). 79 (6·0%)of 1325 patients in the atrasentan group and 105 (7·9%)of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR]0·65 [95% CI 0·49–0·88]; p=0·0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3·5%)of 1325 patients in the atrasentan group and 34 (2·6%)of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85–2·07]; p=0·208). 58 (4·4%)patients in the atrasentan group and 52 (3·9%)in the placebo group died (HR 1·09 [95% CI 0·75–1·59]; p=0·65). Interpretation: Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease. Funding: AbbVie

DataSheet_1_Spatial variation in spawning timing for multi-species Acropora assemblages in the Red Sea.pdf

Sexual reproduction is a crucial process for reef building coral populations to maximize genetic diversity and recover from large scale disturbances. Mass spawning events by Acropora species represent critical opportunities for populations to persist, and a process that is increasingly exploited to actively restore degraded reefs. However, the timing and predictive capacity of coral spawning throughout the broad thermal and environmental regime of the Red Sea – a region also undergoing significant development and active reef restoration – remains patchy. We, therefore, conducted three parallel reef surveys in the central Red Sea (Al-Fahal Reef, Thuwal - Saudi Arabia) and the eastern (Shushah Island - Saudi Arabia) and western (Hurghada – Egypt) coast of the northern Red Sea. Surveys assessed the gravidity of gonads, spawning timing, alignment with the lunar cycle of 21 Acropora spp. (total n= 572 colonies) around the full moons of April and May 2023. Consistent with past observations, synchronous spawning was observed for Acropora spp. in both the central and northern Red Sea during April and May, respectively. Interestingly, corals spawned on the full moon in both Shushah and Thuwal sites. In contrast, corals in Hurghada were independent of the lunar cycle and spawned 7-9 nights before the full moon in May. By integrating our 2023 observations with the historical spawning events in Hurghada and Thuwal (2002-2022), we found that the deviation of spawning timing from the full moon day was correlated with absolute Sea Surface Temperature (SST) (earlier spawning before the full moon day, lower SST) and warming rate (earlier spawning, more rapid warming) in 6-weeks prior to spawning. As such, temperature pattern is likely one of the primary factors governing gamete release, among other factors, that likely influence spawning day within the lunar month. These correlations between SST metrics and spawning timing suggest a potential framework to predict future Acropora spp. spawning dates. Our observations demonstrate the importance of parallel efforts across borders to collect critical data needed to inform management strategies aimed at conserving and restoring coral reefs in this ecologically diverse region.</p